Star Health’s Underwriting Turnaround: 95.7% Q4 Combined Ratio

Star Health and Allied Insurance Company Limited — Q4 & FY2026 Earnings Call (Apr 29, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly highlights “green shoots” and a “turnaround of our underwriting results,” with sequential improvement in loss ratio/combined ratio.
• Confidence language is frequent: “We remain confident,” “we are well placed,” “proceeding in the right direction.”
• Even when discussing volatility (equity MTM loss), they frame it as manageable and introduce a “normalized investment yield” to smooth earnings optics.

2. Key Themes from Management Commentary

• Strategic recalibration across core levers: distribution, strict underwriting discipline, claims management, customer experience, and operating efficiency.
• Retail health structural tailwinds: GST exemption on retail health, rising consumer intent, and regulator reforms (notably IND AS from Apr 1, 2026).
• Underwriting turnaround evidenced by metrics:
• Q4 combined ratio improved to 95.7% (from 98.4% in Q4 FY25).
• Full-year combined ratio improved to 98.8% (from 101.1% in FY25).
• Loss ratio improved to 68.7% (from 70.7% in FY25).
• Quality of growth focus (not just scale):
• New-to-insurance mix remains very high: 93% (FY26 fresh premium basis).
• Continued emphasis on preferred geographies/segments and risk-first approach.
• Claims frequency/severity management via wellness + home/telemedicine:
• Telemedicine/Home Healthcare utilization scaled sharply (management cites 4x–5x overall and ~9x in Q4).
• Positioning: prevention reduces cost of servicing while improving customer outcomes.
• Digital and distribution productivity:
• Digitalized acquisition: 95% of fresh premiums collected digitally.
• Customer app scale: 14M downloads, 1.5M+ MAUs.
• Agency expansion plan: move towards ~1 million agents in next two years.
• Earnings optics management under IND AS / investment volatility:
• Equity market MTM loss acknowledged (Q4 marked-to-market loss Rs. 558 crore).
• Introduction of normalized investment yield pegged at 8% to depict underlying profitability.

3. Q&A Analysis

Theme A: Pathway to further loss ratio improvement (from ~68% retail LR)

• Core question(s):
• Can retail loss ratio move from ~68% to 65–66% (levels seen in 2023–24)?
• Is improvement structural or cyclical (seasonality, NEP unwinding)?
• Management response:
• Claims frequency/severity cycles acknowledged; management argues they are “well placed” due to actions over “last one and a half years.”
• Wellness interventions (Telemedicine/Home Healthcare/Condition Management) cited as key driver; utilization scaled materially.
• They avoid committing to a specific LR target, emphasizing longer-term view and quarterly fluctuations.
• Evasive/partial/strong points:
• Partial: They do not provide a quantified LR “waterfall” to 65–66%, despite the question.
• Strong: Quantified usage—90,000+ Telemedicine/Home Healthcare calls (and 40,000+ pure telemedicine calls)—supports the mechanism.

Theme B: Claims cycle risk (vector-borne seasonality / recurrence)

• Core question(s):
• With lower seasonal claims this year, how will they mitigate if seasonal claims rise again into 2027?
• Management response:
• Focus on prevention/wellness programs and home/telemedicine to manage fever/infection-related cases at home and reduce cost of servicing.
• Frames as ongoing investment and “continuous improvement,” not a one-off fix.
• Evasive/partial/strong points:
• Evasive: No explicit scenario-based mitigation plan or quantified sensitivity to seasonal recurrence.

Theme C: Growth quality vs industry growth gap; NEP vs GWP

• Core question(s):
• Why is Star’s growth lagging industry despite tailwinds?
• Will loss ratio improvement sustain as NEP unwinds?
• Why does NEP growth lag GWP; when to reach ~15% NEP growth?
• Management response:
• “Quality of growth” emphasized: new-to-insurance mix and risk-first selection; “going slow” in some geographies.
• Loss ratio improvement expected to continue overall, with quarter-to-quarter fluctuations.
• NEP lag attributed to long-term policy sales (long-term policies create a lag effect in NEP accounting).
• Evasive/partial/strong points:
• Partial: They state NEP will “catch up” but do not give a firm timeline to 15% NEP growth (they explain accounting mechanics instead).

Theme D: Commission / EoM / regulatory impacts

• Core question(s):
• What drives commission ratio improvement beyond senior citizen commission adjustments?
• How will EoM/commission regulation affect them given they operate within current guidelines?
• Bima Sugam platform implications; regulatory stance on non-compliant players.
• Management response:
• Senior citizens ~20% of portfolio; commission reduction effective April FY25–FY26 window.
• Additional lever: improved sales manager productivity and cost control on sourcing.
• For EoM: “await IRDAI’s guidance,” emphasize discipline and compliance; avoid commenting on regulator enforcement.
• Bima Sugam: supportive; platform aims to reduce consumer friction and provide affordable plans (they are a shareholder).
• Evasive/partial/strong points:
• Evasive: “very difficult question… give it a pass” on regulator enforcement for non-compliant players.
• Strong: Clear attribution of commission improvement to senior citizen adjustment + productivity initiatives.

Theme E: Pricing strategy sustainability vs medical inflation

• Core question(s):
• Do they foresee major repricing needs in FY27 (beyond normal annual increases)?
• How do they ensure pricing doesn’t overlap GST optics?
• Management response:
• Pricing corrections ongoing; they “do not foresee any particular change” beyond normal strategy.
• GST benefits fully passed to consumers; pricing based on product performance/loss ratios, not GST.
• Evasive/partial/strong points:
• Strong: Explicit separation of GST optics vs actuarial pricing basis.

Theme F: Long-term policy accounting / deferred revenue / NEP mix

• Core question(s):
• Long-term vs annual mix; NEP new vs renewal share.
• Deferred revenue quantum for long-term policies.
• Management response:
• NEP new/renewal ratio: around 80:20 (with small premium-basis changes).
• Deferred revenue: offered to share offline.
• Evasive/partial/strong points:
• Partial: Deferred revenue not quantified in-call.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Normalized investment yield: 8% annualized (used to depict underlying profitability excluding short-term MTM volatility).
• Agent growth target: “confident of getting to 1 million in the next two years” (qualitative but numeric target).
• Normalized profitability metric: Under normalized framework, FY26 PAT Rs. 1,222 crore and ROE 13.1% (reported, not forward guidance).

Implicit signals (qualitative)

• Loss ratio trajectory: management expects continued improvement “overall” but acknowledges cyclical fluctuations.
• Pricing: continue annual price increases; no expectation of extraordinary repricing in FY27.
• NEP catch-up: long-term policy accounting will cause NEP lag, but it should “catch up in upcoming quarters.”
• Claims management: continued scaling of telemedicine/home healthcare and prevention to mitigate frequency/severity cycles.

5. Standout Statements (most revealing)

• Turnaround framing: “green shoots… now more pronounced” and “turnaround of our underwriting results.”
• Combined ratio milestone: “combined ratio… came to 98.8% in FY26” (from 101.1% in FY25).
• Normalized earnings approach: “adopting… normalized investment yield, pegged at 8%… excluding short-term fluctuations.”
• Mechanism for frequency reduction: “Telemedicine… Home Healthcare… 4x to 5x jump… Q4… almost a 9x jump.”
• NEP lag explanation: “long-term policy sales… preferred… NEP growth will have a lag effect.”
• No extraordinary repricing: “We do not foresee any particular change… beyond normal.”
• Regulatory stance: “await IRDAI’s guidance on EoM” and they are “probably the only company… within current guidelines.”

6. Red Flags / Positive Signals

Red flags
– No hard forward LR/combined ratio targets: repeated refusal to quantify “pathway” to 65–66% retail LR.
– Earnings smoothing via normalized yield: while reasonable, it can mask volatility-driven earnings swings (they explicitly introduce normalization).
– Deferred revenue and some mix details moved offline: key items not fully disclosed in-call (e.g., deferred revenue quantum).

Positive signals
– Clear, quantified operational drivers (telemedicine call counts; utilization scaling).
– Consistent underwriting improvement across quarters (Q2/Q3/Q4 retail LR improvement cited sequentially).
– Strong new-to-insurance mix (93–94% fresh premium basis), supporting quality growth narrative.

7. Historical Comparison & Consistency Analysis

a. Change in Tone Over Time

• Current call (Apr 29, 2026): more Optimistic—management claims turnaround is now “more pronounced” and “sustainable” via underlying metrics.
• Prior calls:
• Q1 FY26 (Jul 30, 2025): confident but framed as “measures… yielding results” with ongoing elevated industry costs; less evidence of turnaround.
• Q2 & H1 FY26 (Oct 29, 2025): optimistic but still emphasized early results; loss ratio improvement described as progressing.
• Q3 & 9M FY26 (Jan 29, 2026): strong improvement narrative (combined ratio improvement, underwriting profit swing), but still more “trajectory” than “confirmed.”
• Shift classification: More Optimistic
• Language moved from “green shoots / trajectory” to “turnaround… now more pronounced.”
• Greater willingness to introduce a normalized earnings framework suggests management is confident enough to manage optics proactively.

b. Tracking Past Commitments vs Outcomes

• Past statement (Q1 FY26 / earlier): focus on annual repricing and portfolio recalibration; expected loss ratio improvement over time.
• Outcome in current call: loss ratio and combined ratio improved materially in FY26 (combined ratio 98.8%; retail LR 68.2%).
• Flag: ✅ Delivered (directionally; though not to the 65–66% target asked by analysts).
• Past statement (Q3 FY26 / earlier): continued improvement in loss ratios quarter-on-quarter.
• Outcome: sequential retail loss ratio improvements cited for Q2/Q3/Q4 FY26.
• Flag: ✅ Delivered (sequential improvement).
• Past statement (Q2 FY26): GST waiver expected to drive demand and persistency improvements.
• Outcome: renewal retention and retention-related commentary improved; management cites retention and higher sum insured/riders (in Q&A).
• Flag: ✅ Delivered (qualitative support; no full quantified persistency table in-call).

c. Narrative Shifts

• From “pricing + underwriting corrections” to “wellness/telemedicine as frequency lever”:
• Earlier calls emphasized pricing corrections, underwriting, and FWA.
• Current call elevates telemedicine/home healthcare utilization as a central mechanism for frequency reduction and claims cost control.
• From “awaiting IFRS regime” to “enter IND AS from readiness”:
• Current call stresses IND AS readiness and uses normalized yield to manage IFRS volatility optics.
• NEP/GWP accounting narrative becomes more prominent:
• Current call repeatedly explains NEP lag due to long-term policies—more explicit than earlier.

d. Consistency & Credibility Signals

• Medium-to-High credibility, but with some caution:
• Consistent: underwriting discipline + risk-first + digital scale are repeated across calls.
• Consistent mechanism: pricing repricing takes time to flow into earned premium/loss ratio—management maintains this explanation.
• Potential credibility gap: they claim “structural” improvement, but still avoid committing to specific LR targets (e.g., 65–66%).
• Overall credibility classification: Medium-High
• Communication is coherent and metric-driven, but forward quantification remains limited.

e. Evolution of Key Themes

• Demand / growth: improving and structurally supported (GST tailwind + new-to-insurance mix).
• Margins / underwriting: clear improvement trend culminating in FY26 underwriting profit turning positive (Rs. 206 crore).
• Claims management: evolution from general claims efficiency to telemedicine/home healthcare utilization as a measurable frequency-control tool.
• Regulatory / accounting: IND AS transition and normalized yield framework introduced to manage volatility.

f. Additional Insights (Cross-Period Intelligence)

• Volatility management is increasing: introduction of normalized investment yield suggests management expects continued MTM swings under IND AS (equity market sensitivity).
• Analyst focus shifted from “is turnaround real?” to “how far can it go?”
• This indicates the market now believes improvement is real, but is pressing for sustainability/ceiling—management still avoids hard targets, implying uncertainty around reaching 65–66% retail LR.
• Long-term policy accounting is now a primary explanation for growth/margin optics:
• NEP lag and retention improvements are increasingly tied to long-term policy preference; this may also mean near-term profitability visibility remains constrained by accounting timing.